| 2026-08-13 | Press release | Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Cr |
| 2026-08-03 | Press release | Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competi |
| 2026-07-21 | Press release | Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readi |
| 2026-07-13 | Press release | Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for |
| 2026-06-30 | Press release | Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules |
| 2026-06-24 | Press release | Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Con |
| 2026-06-18 | Press release | Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease |
| 2026-06-15 | Press release | Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) C |
| 2026-06-03 | Press release | Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 |
| 2026-05-19 | Press release | Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 |
| 2026-05-07 | Press release | Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 F |
| 2026-05-04 | Presentation | Download Investor Presentation |
| 2026-04-30 | Press release | Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 i |
| 2026-03-31 | Press release | Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for H |
| 2026-03-12 | Press release | Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Di |
| 2026-03-02 | Press release | Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion |
| 2026-02-24 | Press release | Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, S |
| 2026-01-12 | Press release | Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at |
| 2025-12-17 | Press release | Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conferen |
| 2025-12-11 | Press release | Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thr |
| 2025-12-01 | Press release | Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors |
| 2025-11-19 | Press release | Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award |
| 2025-11-10 | Press release | Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-09-29 | Investor meeting | Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 |
| 2025-09-29 | Press release | Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 |
| 2025-09-15 | Press release | Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibi |
| 2025-08-11 | Press release | Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-08-05 | Press release | Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease |
| 2025-06-12 | Press release | Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients |
| 2025-06-04 | Press release | Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 |
| 2025-05-15 | Press release | Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness |
| 2025-04-17 | Press release | Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq |
| 2025-04-03 | Press release | Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences |
| 2025-03-04 | Press release | Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patient |
| 2025-02-05 | Press release | Cadrenal Therapeutics to Present at BIO CEO & Investor Conference |
| 2025-01-13 | Press release | Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 |
| 2024-12-18 | Press release | Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and I |
| 2024-11-12 | Press release | CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRE |
| 2024-11-07 | Press release | CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE |
| 2024-11-01 | Press release | Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds |